Literature DB >> 28368289

Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Anna C Groner, Myles Brown.   

Abstract

Steroid hormones mediate critical lineage-specific developmental and physiologic responses. They function by binding their cognate receptors, which are transcription factors that drive specific gene expression programs. The requirement of most prostate cancers for androgen and most breast cancers for estrogen has led to the development of endocrine therapies that block the action of these hormones in these tumors. While initial endocrine interventions are successful, resistance to therapy often arises. We will review how steroid receptor-dependent genomic signaling is affected by genetic alterations in endocrine therapy resistance. The detailed understanding of these interactions will not only provide improved treatment options to overcome resistance, but, in the future, will also be the basis for implementing precision cancer medicine approaches.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28368289      PMCID: PMC5373886          DOI: 10.1172/JCI88885

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  136 in total

1.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

2.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

3.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

4.  Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Authors:  Mathieu Lupien; Clifford A Meyer; Shannon T Bailey; Jérôme Eeckhoute; Jennifer Cook; Thomas Westerling; Xiaoyang Zhang; Jason S Carroll; Daniel R Rhodes; X Shirley Liu; Myles Brown
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

5.  FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.

Authors:  Yusuke Imamura; Shinichi Sakamoto; Takumi Endo; Takanobu Utsumi; Miki Fuse; Takahito Suyama; Koji Kawamura; Takashi Imamoto; Kojiro Yano; Katsuhiro Uzawa; Naoki Nihei; Hiroyoshi Suzuki; Atsushi Mizokami; Takeshi Ueda; Naohiko Seki; Hideki Tanzawa; Tomohiko Ichikawa
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

6.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.

Authors:  Say Li Kong; Guoliang Li; Siang Lin Loh; Wing-Kin Sung; Edison T Liu
Journal:  Mol Syst Biol       Date:  2011-08-30       Impact factor: 11.429

7.  Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells.

Authors:  Peter Dudek; Didier Picard
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

Review 8.  Pioneer transcription factors in cell reprogramming.

Authors:  Makiko Iwafuchi-Doi; Kenneth S Zaret
Journal:  Genes Dev       Date:  2014-12-15       Impact factor: 11.361

9.  FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression.

Authors:  J C Zhao; K-W Fong; H-J Jin; Y A Yang; J Kim; J Yu
Journal:  Oncogene       Date:  2016-01-11       Impact factor: 9.867

10.  Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

Authors:  Nathalie Quenel-Tueux; Marc Debled; Justine Rudewicz; Gaetan MacGrogan; Marina Pulido; Louis Mauriac; Florence Dalenc; Thomas Bachelot; Barbara Lortal; Christelle Breton-Callu; Nicolas Madranges; Christine Tunon de Lara; Marion Fournier; Hervé Bonnefoi; Hayssam Soueidan; Macha Nikolski; Audrey Gros; Catherine Daly; Henry Wood; Pamela Rabbitts; Richard Iggo
Journal:  Br J Cancer       Date:  2015-07-14       Impact factor: 7.640

View more
  15 in total

1.  FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.

Authors:  Amaia Arruabarrena-Aristorena; Jesper L V Maag; Srushti Kittane; Yanyan Cai; Wouter R Karthaus; Erik Ladewig; Jane Park; Srinivasaraghavan Kannan; Lorenzo Ferrando; Emiliano Cocco; Sik Y Ho; Daisylyn S Tan; Mirna Sallaku; Fan Wu; Barbara Acevedo; Pier Selenica; Dara S Ross; Matthew Witkin; Charles L Sawyers; Jorge S Reis-Filho; Chandra S Verma; Ralf Jauch; Richard Koche; José Baselga; Pedram Razavi; Eneda Toska; Maurizio Scaltriti
Journal:  Cancer Cell       Date:  2020-09-03       Impact factor: 31.743

2.  Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.

Authors:  Qilong Tan; Ziqun Liu; Xiaobo Gao; Yibo Wang; Xuefeng Qiu; Jiahui Chen; Liuchun Liang; Hongqian Guo; Shengsong Huang; Denglong Wu; Bing Zhou; Ronggui Hu; Zhenfei Li
Journal:  Oncogene       Date:  2022-09-16       Impact factor: 8.756

Review 3.  X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.

Authors:  Rossella Tricarico; Emmanuelle Nicolas; Michael J Hall; Erica A Golemis
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 12.531

4.  TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.

Authors:  Lin Wang; Bo Han; Tingting Feng; Ru Zhao; Feifei Sun; Qiqi Lu; Xueli Wang; Jing Hu; Shiguan Wang; Lin Gao; Qianqian Zhou; Xueting Xiong; Xuesen Dong
Journal:  Oncogene       Date:  2019-09-02       Impact factor: 9.867

5.  A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance.

Authors:  Emmanuel Rosas; Justin T Roberts; Kathleen I O'Neill; Jessica L Christenson; Michelle M Williams; Toru Hanamura; Nicole S Spoelstra; Jeffery M Vahrenkamp; Jason Gertz; Jennifer K Richer
Journal:  Endocrinology       Date:  2021-02-01       Impact factor: 4.736

Review 6.  Exploring Protein⁻Protein Interaction in the Study of Hormone-Dependent Cancers.

Authors:  Yasuhiro Miki; Erina Iwabuchi; Katsuhiko Ono; Hironobu Sasano; Kiyoshi Ito
Journal:  Int J Mol Sci       Date:  2018-10-15       Impact factor: 5.923

7.  Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly.

Authors:  Pia Giovannelli; Marzia Di Donato; Ferdinando Auricchio; Gabriella Castoria; Antimo Migliaccio
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

8.  Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells.

Authors:  Andrés M Castellaro; María C Rodriguez-Baili; Cecilia E Di Tada; Germán A Gil
Journal:  Cancers (Basel)       Date:  2019-02-06       Impact factor: 6.639

9.  Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids.

Authors:  Wenxiang Hu; Chunjie Jiang; Mindy Kim; Wenjian Yang; Kun Zhu; Dongyin Guan; Wenjian Lv; Yang Xiao; Jessica R Wilson; Daniel J Rader; Ching-Hon Pui; Mary V Relling; Mitchell A Lazar
Journal:  Cell Metab       Date:  2021-07-06       Impact factor: 31.373

Review 10.  Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.

Authors:  Jun Yang; Adrian L Harris; Andrew M Davidoff
Journal:  Int J Mol Sci       Date:  2018-01-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.